High Diagnostic Accuracy of Visible 5-ALA Fluorescence in Meningioma Surgery According to Histopathological Analysis of Tumor Bulk and Peritumoral Tissue.
5-ALA
fluorescence
histopathology
meningioma
peritumoral tissue
tumor bulk
Journal
Lasers in surgery and medicine
ISSN: 1096-9101
Titre abrégé: Lasers Surg Med
Pays: United States
ID NLM: 8007168
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
revised:
16
06
2020
received:
15
05
2020
accepted:
18
06
2020
pubmed:
2
7
2020
medline:
29
10
2021
entrez:
2
7
2020
Statut:
ppublish
Résumé
Complete neurosurgical resection of intracranial meningiomas is essential to avoid residual tumor tissue and thus minimize the risk of tumor recurrence. However, local recurrence of meningiomas is not uncommon mainly due to insufficient intraoperative detection of residual tumor tissue within the tumor bulk or peritumoral tissue such as bone and satellite lesions. Although 5-aminolevulinic acid (5-ALA) induced fluorescence was found to visualize the majority of meningiomas, no comprehensive histopathological assessment of fluorescing samples from the tumor bulk and peritumoral tissue is available. The aim of our study was thus to histopathologically analyze a large series of tissue samples derived from meningioma surgery to assess the positive predictive value (PPV) of visible 5-ALA fluorescence. In this study, we retrospectively investigated a series of tissue samples with visible 5-ALA fluorescence collected during surgery of intracranial meningiomas from the tumor bulk and peritumoral tissue including the bone flap, dura/dural tail, arachnoidea, adjacent cortex, and satellite lesions. The tumor diagnosis was established according to the World Health Organization (WHO) criteria and all collected fluorescing samples were screened for presence of tumor tissue to calculate the PPV. Altogether, 191 tissue samples with visible 5-ALA fluorescence derived during surgery of 85 meningiomas (63 WHO grade I, 17 WHO grade II, and 5 WHO grade III) were included. In detail, 158 samples from the tumor bulk and 33 specimens from the peritumoral tissue were investigated. According to histopathological analysis, the PPV of 5-ALA fluorescence was significantly higher in samples from the tumor bulk (100%) as compared with peritumoral tissue (73%; P < 0.001). With regard to peritumoral tissue, tumor tissue was present in most fluorescing samples from the satellite lesions (100%), the bone flap (92%), arachnoidea (83%), and dura/dural tail (75%). In contrast, tumor tissue was absent in the majority of samples from fluorescing cortex (six of seven samples; 86%). However, distinct reactive tissue alterations were found in all six tumor-free fluorescing cortex samples and additional vascular proliferation in two cases. In this largest series to date, visible 5-ALA fluorescence is characterized by a high PPV detecting tumor bulk and peritumoral tissue in intracranial meningiomas. Thus, 5-ALA fluorescence supports the neurosurgeon in identifying residual tumor tissue at relevant surgical sites to optimize meningioma surgery and minimize the risk of local recurrence. © 2020 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.
Sections du résumé
BACKGROUND AND OBJECTIVES
Complete neurosurgical resection of intracranial meningiomas is essential to avoid residual tumor tissue and thus minimize the risk of tumor recurrence. However, local recurrence of meningiomas is not uncommon mainly due to insufficient intraoperative detection of residual tumor tissue within the tumor bulk or peritumoral tissue such as bone and satellite lesions. Although 5-aminolevulinic acid (5-ALA) induced fluorescence was found to visualize the majority of meningiomas, no comprehensive histopathological assessment of fluorescing samples from the tumor bulk and peritumoral tissue is available. The aim of our study was thus to histopathologically analyze a large series of tissue samples derived from meningioma surgery to assess the positive predictive value (PPV) of visible 5-ALA fluorescence.
STUDY DESIGN/MATERIALS AND METHODS
In this study, we retrospectively investigated a series of tissue samples with visible 5-ALA fluorescence collected during surgery of intracranial meningiomas from the tumor bulk and peritumoral tissue including the bone flap, dura/dural tail, arachnoidea, adjacent cortex, and satellite lesions. The tumor diagnosis was established according to the World Health Organization (WHO) criteria and all collected fluorescing samples were screened for presence of tumor tissue to calculate the PPV.
RESULTS
Altogether, 191 tissue samples with visible 5-ALA fluorescence derived during surgery of 85 meningiomas (63 WHO grade I, 17 WHO grade II, and 5 WHO grade III) were included. In detail, 158 samples from the tumor bulk and 33 specimens from the peritumoral tissue were investigated. According to histopathological analysis, the PPV of 5-ALA fluorescence was significantly higher in samples from the tumor bulk (100%) as compared with peritumoral tissue (73%; P < 0.001). With regard to peritumoral tissue, tumor tissue was present in most fluorescing samples from the satellite lesions (100%), the bone flap (92%), arachnoidea (83%), and dura/dural tail (75%). In contrast, tumor tissue was absent in the majority of samples from fluorescing cortex (six of seven samples; 86%). However, distinct reactive tissue alterations were found in all six tumor-free fluorescing cortex samples and additional vascular proliferation in two cases.
CONCLUSION
In this largest series to date, visible 5-ALA fluorescence is characterized by a high PPV detecting tumor bulk and peritumoral tissue in intracranial meningiomas. Thus, 5-ALA fluorescence supports the neurosurgeon in identifying residual tumor tissue at relevant surgical sites to optimize meningioma surgery and minimize the risk of local recurrence. © 2020 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.
Identifiants
pubmed: 32608510
doi: 10.1002/lsm.23294
pmc: PMC8048546
doi:
Substances chimiques
Aminolevulinic Acid
88755TAZ87
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
300-308Informations de copyright
© 2020 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.
Références
Lancet Oncol. 2006 May;7(5):392-401
pubmed: 16648043
Acta Neurochir (Wien). 1998;140(10):995-1000
pubmed: 9856241
Eur J Radiol. 2009 Apr;70(1):10-6
pubmed: 18294796
J Neurosurg. 2014 Apr;120(4):840-5
pubmed: 24410157
Neurosurg Focus. 2014 Feb;36(2):E10
pubmed: 24484248
J Neurooncol. 2009 Dec;95(3):401-411
pubmed: 19562257
World Neurosurg. 2017 Dec;108:118-127
pubmed: 28866060
J Neurosurg. 1986 Jan;64(1):58-63
pubmed: 3941351
Radiology. 1990 May;175(2):431-3
pubmed: 2326470
Brain Tumor Pathol. 2006 Apr;23(1):13-7
pubmed: 18095114
Acta Neurochir (Wien). 2017 Jun;159(6):1027-1031
pubmed: 28397137
J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39
pubmed: 13406590
Neurosurgery. 2015 Nov;77(5):663-73
pubmed: 26308630
Neurosurgery. 1999 Apr;44(4):742-6; discussion 746-7
pubmed: 10201298
Photodiagnosis Photodyn Ther. 2014 Dec;11(4):481-90
pubmed: 25117928
Neuroradiology. 2001 Jun;43(6):462-5
pubmed: 11465757
Neuro Oncol. 2017 Oct 1;19(10):1298-1307
pubmed: 28419308
J Neurosurg. 2012 Jul;117(1):121-8
pubmed: 22559847
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
J Neurooncol. 2019 Feb;141(3):555-565
pubmed: 30604395
J Neurosurg. 2007 Jun;106(6):1070-4
pubmed: 17564181
PLoS One. 2013 Oct 18;8(10):e76988
pubmed: 24204718
J Neurosurg. 1986 Aug;65(2):168-71
pubmed: 3723173
J Neurosurg. 2018 Aug;129(2):341-353
pubmed: 29076783
Neurosurgery. 2016 Mar;78(3):401-11; discussion 411
pubmed: 26366972
Neuro Oncol. 2012 May;14(5):658-66
pubmed: 22406926
Clin Neurol Neurosurg. 2011 Sep;113(7):541-7
pubmed: 21507562
Cancer. 2010 Mar 15;116(6):1545-52
pubmed: 20108311
Zh Vopr Neirokhir Im N N Burdenko. 2018;82(2):17-29
pubmed: 29795083
Neurosurgery. 2019 Jun 1;84(6):1214-1224
pubmed: 30107580
J Neurosurg. 2016 Dec;125(6):1408-1419
pubmed: 27015401
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
World Neurosurg. 2011 Dec;76(6):564-71
pubmed: 22251505
Neurosurgery. 2014 Mar;10 Suppl 1:74-82; discussion 82-3
pubmed: 23887194
J Neurosurg. 2019 May 10;:1-10
pubmed: 31075771
Opt Lett. 2013 Aug 1;38(15):2786-8
pubmed: 23903142